Skip to main content
Premium Trial:

Request an Annual Quote

Directif Partners with Epidauros to Market Its LabChip for Clinical Diagnostics

NEW YORK, March 23 (GenomeWeb News) - Directif GmbH and Epidauros Biotechnology have signed a co-development and co-marketing agreement for Directif's LabChip technology, the firms said today.


Epidauros, a provider of pharmacogenetic assays and services, will partner with Directif, a subsidiary of November AG based in Erlangen, Germany, to create "client-specific" applications for the LabChip technology, which offers automated analysis of nucleic acids for clinical diagnostic applications.


Bernried, Germany-based Epidauros said that it will market the LabChip to its established clientele of international pharmaceutical companies. Epidauros licensed a genetic polymorphism to Roche in November 2004 for use in its AmpliChip CYP450 test.


Financial details of the collaboration were not discussed.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.